 |
Project NextGen — Defeating SARS-CoV-2 and Preparing for the Next Pandemic George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak. |
 |
George Washington University Recruiting Teens For Mpox Vaccine Clinical TrialRead more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak. DCist, April 20, 2023 |
 |
Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trialRead more about the new hope found in Phase 1 clinical trials for the HIV vaccine. News Medical, Dec. 8, 2022 |
 |
NIH trials seek answers on monkeypox vaccine deliveryHere is more information about the NIH trials and what Dr. Diemert and other infectious disease experts have to say about the progress in the monkeypox vaccine. Healio, Sep. 21, 2022 |
 |
NIH and GW University recruiting volunteers for monkeypox vaccine trials Check out this interview with our very own Dr. Diemert, the director of the GW Vaccine Research Unit on WTOP to learn more about our current monkeypox trial. WTOP, Sep. 20, 2022 |
 |
Americans likely to need COVID-19 booster, officials say, but questions abound Dr. Diemert and other infectious disease experts discuss the search for a universal COVID-19 vaccine and comparisons to the seasonal influenza vaccine. Healio, Sep. 8, 2022 |
 |
Clinical Trial Evaluating Monkeypox Vaccine Begins NIH Trial is Evaluating Intradermal Delivery to Expand the Vaccine Supply. National Institute of Health, Sep. 8, 2022 |
 |
Monkeypox Myths and Facts: What You Need to Know Doreen Gentzler, NBC4 News Anchor, interviews GW VRU Director, Dr. David Diemert on monkeypox myths and facts. NBC4 Washington, Aug. 24, 2022 |
 |
FDA Clears Moderna, Pfizer Covid Shots for Children 5 and Under Long-awaited protection for tots appears close to arrival. Moderna also get clearance for vaccine for 6- to 17-year olds. Bloomberg, June 17, 2022 |
 |
The Most Common Questions About The Novavax COVID Vaccine, Answered How is the shot different from Pfizer, Moderna and J&J? Does it work against new variants? Here's what to know. Huffpost, June 10, 2022 |
 |
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern. Moderna, Inc., June 8 2022 |
 |
The GW School of Medicine and Health Sciences has been selected to serve as one of 24 participating sites for the Phase 2 clinical trial to evaluate additional COVID-19 booster shots in adults, including multiple vaccines based on viral variants such as Delta and Omicron. GW School of Medicine & Health Sciences, April 8, 2022 |
 |
The hunt for an AIDS vaccine approaches 40 with hope and caution Scientists created a COVID-19 vaccine in under a year, but there remains no vaccine to stop the AIDS virus. Experts explain how HIV eludes defeat and describe their latest strategies. AAMC, March 31, 2022 |
 |
NIH Begins Clinical Trial Evaluating Second COVID-19 Booster Shots in Adults A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. National Institute of Health, March 31, 2022 |
 |
First Patients Vaccinated in Clinical Trial of Experimental HIV Vaccine Dr. David Diemert, director of The GW Vaccine Research Unit, was interviewed on CTV Your Morning about our current clinical trial of an experimental HIV vaccine. “The future implications are huge if we could have an effective HIV vaccine that would prevent people from getting the infection and thereby not having to go on antiretroviral medication for the rest of their lives,” he says. CTV Your Morning, February 10, 2022 |
 |
University administers first doses of mRNA HIV vaccine through Moderna partnership GW was one of the first institutions in the country to administer doses of the first mRNA HIV vaccines to human participants late last month. GW Hatchet, February 7, 2022 |
 |
GW Participating in the First Human Trial of mRNA-based HIV Vaccine Early study will test the safety of an experimental HIV vaccine using the same mRNA technology as used in the highly effective COVID-19 vaccines. GW Today, January 27, 2022 |
 |
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. Moderna, January 27, 2022 |
 |
Q&A: Vaccine Researcher David Diemert, MD The Clinical Director of the GW Vaccine Research Unit Discussed the Delta Variant and the Fourth Wave of the COVID-19 Pandemic GW School of Medicine & Health Sciences, August 31, 2021 |
 |
SMHS-Led Clinical Trial To Assess Immunogenicity and Safety of Lassa Fever Vaccine A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences. With an award from trial sponsor IAVI, Malkin, along with collaborators from Brigham and Women’s Hospital in Boston, Redemption Hospital in Monrovia, Liberia, and East-West Medical Research Institute in Honolulu, Hawaii, will be testing IAVI’s experimental vaccine candidate called “rVSV∆G-LASV-GPC,” a recombinant vesicular stomatitis virus (rVSV) vector-based vaccine expressing a Lassa virus protein (LASV-GPC). GW School of Medicine & Health Sciences, August 30, 2021 |
 |
The first mRNA-based HIV vaccine is about to start human trials The same system Moderna used for its COVID vaccine may also be able to help prevent HIV. Popular Science, August 18, 2021 |
 |
George Washington University to Participate in Sanofi Phase II COVID-19 Vaccine Trial GW will be a clinical trial site for Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate. GW School of Medicine & Health Sciences, March 2, 2021 |
 |
Multidisciplinary effort boosts the George Washington University COVID-19 vaccine clinical trial. GW School of Medicine & Health Sciences, February 1, 2021 |
 |
GWU’s covid-19 clinical trial has met one early goal — getting Black and Latino people to join A critical goal for the Phase 3 clinical trial is also to ensure that the pool of the vaccine test subjects reflects the nation’s diversity, including minorities, older Americans and people with preexisting health conditions. It’s all the more important given the disparate impact the pandemic has had on people who are Black or Latino, as well as other racial minorities. The Washington Post, September 13, 2020 |
 |
Covering Ebola Didn’t Prepare Me for This: I Volunteered for the Covid-19 Vaccine Trial George Washington University invited me to participate in Moderna’s vaccine trial because I am triple-risk: a Black woman, a Type 1 diabetic and asthmatic. The New York Times, September 11, 2020 |
 |
GW Chosen as Site for COVID-19 Phase 3 Vaccine Trial The George Washington University is one of approximately 90 sites chosen for the first Phase 3 clinical trial of a COVID-19 vaccine candidate in the US. Watch: https://wjla.com/news/local/500-covid-19-vaccine-volunteers-needed-for-dc-trial GW School of Medicine & Health Sciences & GW Milken Institute School of Public Health, July 27, 2020 |
 |
Jeff Bethony Interview with Nature Microbiologist and Clinical Immunology Lab Director, Jeffrey Bethony details progress in efforts to protect people from hookworms and schistosomiasis. Nature - Outlook, November 27, 2019 |
 |
GW Serving as Site for HIV Vaccine Trial The George Washington University School of Medicine and Health Sciences is one of only two sites chosen for the first clinical trial of the eOD-GT8 60mer HIV vaccine candidate. GW School of Medicine & Health Sciences, October 11, 2018 |
 |
Schistosoma Vaccine to Enter Phase Ib Clinical Trial A team of researchers at the George Washington University have received funding from the National Institutes of Health for a Phase Ib clinical trial for a Schistosomiasis vaccine in an endemic area of Brazil. GW School of Medicine & Health Sciences, January 18, 2018 |
 |
Trying To Get The World Unhooked From Hookworm This week, Goats and Soda learned of a pretty icky research experiment taking place in our nation's capital. People are becoming infected with hookworm in the name of science, as researchers seek to develop a vaccine. National Public Radio, July 21, 2015 |
 |
GW seeks volunteers to let parasitic worms burrow into their skin. Any takers? Researchers at George Washington University hope to develop a vaccine to prevent an infection that is afflicting more than half a billion people around the world. The Washington Post, July 20, 2015 |
 |
Hookworm Vaccine Trials Begin at GW In a pioneering study, infecting healthy adults is the next step toward eradicating the infection. GW Today, July 6, 2015 |